The SEC announced Nasdaq will halt trading of Windtree Therapeutics (WINT) for failing to meet listing requirements, with the company’s stock moving to the OTC market.
The SEC revealed that Nasdaq will suspend Windtree Therapeutics' trading on August 21, 2025, after the company failed to meet the $1 minimum bid price rule. The company's common stock will be moved to the OTC market under the same ticker, though approval for OTCID listing remains uncertain. Windtree assured that its business operations would continue, and it will keep filing SEC reports. Last month, Windtree secured $520 million in new financing to advance its BNB fund strategy.